Tryptophan
Brand names: Optimax
Tryptophan is an amino acid precursor of serotonin used as an adjunctive treatment in resistant depression, typically under specialist supervision.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
As a precursor in serotonin biosynthesis, it is thought to enhance central serotonergic activity, supplementing the action of conventional antidepressants.
Prescribing in practice
- It has been associated with eosinophilia-myalgia syndrome, so it is restricted to specialist use with monitoring and patient registration in line with the SPC.
- Combined with other serotonergic agents it increases the risk of serotonin syndrome.
- Treatment should be reviewed for benefit, and patients monitored for eosinophilia and myalgic symptoms.
Monitoring
Monitor for eosinophilia-myalgia symptoms, including muscle pain and eosinophil count, and for features of serotonin excess.
Counselling the patient
- Report any unexplained muscle pain, weakness or swelling promptly.
- This medicine is used alongside other antidepressants under specialist guidance.
- Tell your doctor about all other medicines you take, especially other antidepressants.
Evidence & guidelines
The association of tryptophan with eosinophilia-myalgia syndrome underlies its restricted specialist use, as reflected in MHRA and SPC guidance.
Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Acute Behavioural Disturbance / Rapid Tranquillisation · RCEM 2022; RCPsych 2022; NICE NG10
- Self-Harm Presentation · NICE NG225 (2022)
- Capacity Assessment (Mental Capacity Act) · MCA 2005; Code of Practice
- Acute Psychosis Management · NICE CG178 2014
- Depression Management · NICE CG90 2022
- Lithium Therapy Monitoring · NICE CG185